Jazz Pharmaceuticals Plc
A global biopharmaceutical company focused on rare diseases, Jazz Pharmaceuticals makes medicines for sleep disorders, epilepsy, and cancer. Its flagship products include Xywav for narcolepsy, Epidiolex for rare epilepsies, and the newer oncology drugs Ziihera and Modeyso. Founded in 2003 by Bruce Cozadd, the company took its name from the idea of jazz improvisation — innovating freely while staying grounded in a shared structure, much like musicians jamming together on stage.
Sold 70.2K
Bought 1.33M
Bought 1.33M
Bought 1.33M
Bought 1.33M
Granted 2.46M · Bought 306.6K · Sold 1.06M
Sold 6.75M
Sold 6.75M
Bought 100.0K
Granted 55.0K · Bought 296.0K
Bought 190.3K
Granted 61.3K · Bought 201.6K · Sold 3.39M
Granted 2.42M · Bought 10.0K · Sold 649.7K
Granted 8.8K · Bought 28.6K
Granted 8.8K · Bought 6.0K · Sold 20.5K
Granted 197.4K · Sold 8.6K
Granted 358.5K · Bought 53.0K · Sold 82.0K
Granted 218.5K · Sold 33.5K
Granted 138.9K · Sold 18.5K
Granted 50.9K · Bought 12.0K
Granted 6.3K
Granted 86.7K
Granted 177.1K · Bought 15.0K · Sold 31.2K
Granted 157.5K · Sold 79.1K
Granted 94.5K · Sold 28.2K
Granted 52.0K · Sold 106.7K
Granted 140.1K · Sold 67.5K
Granted 103.4K · Sold 54.3K
Granted 59.3K · Sold 20.1K
Granted 358.4K · Sold 149.1K
Granted 25.0K · Sold 24.3K
Granted 1.49M · Bought 206.4K · Sold 1.49M
Granted 45.7K · Sold 9.6K
Granted 29.6K · Bought 1.7K
Granted 39.7K · Sold 9.0K
Granted 41.4K · Sold 25.2K
Granted 35.7K · Sold 12.0K
Granted 21.1K · Sold 9.0K
Granted 4.96M · Bought 988.3K · Sold 2.94M
Granted 143.2K · Sold 77.2K
Granted 42.3K · Sold 20.3K
Granted 42.3K · Sold 21.4K
Granted 29.5K · Sold 1.1K
Granted 29.8K · Sold 14.2K
Granted 22.6K · Sold 2.8K
Granted 31.7K · Sold 15.6K
Granted 38.4K · Sold 23.6K
Granted 20.9K · Sold 5.2K
Granted 709
Sold 93
Granted 25.0K
Granted 17.7K · Sold 3.6K
Granted 17.7K · Sold 4.7K
Granted 136.5K · Sold 66.9K
Granted 113.9K · Sold 51.1K
Granted 12.7K · Sold 4.4K
Granted 7.2K
Granted 8.7K
Granted 42.4K · Sold 38.1K
Granted 690
Granted 1.5K
Sold 70.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| KKR & Co. L.P. +5 co-filersReporting owner · 3 transactions | — | 9.94Mas of Sep 2011 | — | — | 70.2K |
| Calbert Michael M +9 co-filerssee footnotes, see footnotes (2) - (7) · 3 transactions | — | 9.94Mas of Jul 2008 | — | 1.33M | — |
| Greene James H Jr +9 co-filerssee footnotes (2) - (7), see footnotes · 3 transactions | — | 9.94Mas of Jul 2008 | — | 1.33M | — |
| Greene James H Jr +9 co-filerssee footnotes (2) - (7) · 1 transaction | — | 9.94Mas of Jul 2008 | — | 1.33M | — |
| Janetschek William J +1 co-filersee footnotes (2) - (7) · 1 transaction | — | 9.94Mas of Jul 2008 | — | 1.33M | — |
| Clammer Adam +9 co-filersDirector, See Footnotes 5,6&7 · 2 transactions | — | 8.61Mas of Jun 2007 | — | — | — |
| Cressey Bryan CReporting owner · 21 transactions | — | 3.91Mas of Mar 2012 | 2.46M | 306.6K | 1.06M |
| KKR & Co. L.P. +9 co-filersReporting owner · 6 transactions | — | 3.19Mas of Mar 2013 | — | — | 6.75M |
| KKR III GP LLC +4 co-filersReporting owner · 6 transactions | — | 3.19Mas of Mar 2013 | — | — | 6.75M |
| Bridger Capital LLC +4 co-filers10% owner · 9 transactions | — | 2.67Mas of Apr 2008 | — | 100.0K | — |
| Cressey Bryan C +3 co-filersDirector, 10% owner · 1 transaction | — | 1.99Mas of Jun 2007 | — | — | — |
| Colella Samuel DDirector · 15 transactions | — | 1.57Mas of Jan 2012 | 55.0K | 296.0K | — |
| Tananbaum James BDirector · 6 transactions | — | 1.42Mas of Jul 2008 | — | 190.3K | — |
| Mulligan SeamusDirector · 106 transactions | — | 1.28M | 61.3K | 201.6K | 3.39M |
| Cozadd Bruce CDirector · 283 transactions | — | 372.7K | 2.42M | 10.0K | 649.7K |
| Saks Samuel RChief Executive Officer, Director · 23 transactions | — | 358.9Kas of Nov 2008 | 8.8K | 28.6K | — |
| Myers Robert MPresident, Director · 19 transactions | — | 156.9Kas of Nov 2010 | 8.8K | 6.0K | 20.5K |
| Gala Renee DPresident & CEO · 30 transactions | — | 152.2K | 197.4K | — | 8.6K |
| Falberg Kathryn EEVP and CFO · 33 transactions | — | 133.4Kas of Mar 2014 | 358.5K | 53.0K | 82.0K |
| Cox Russell J.EVP & COO · 50 transactions | — | 102.8Kas of Dec 2017 | 218.5K | — | 33.5K |
| Iannone RobertEVP, Global Head of R&D & CMO · 30 transactions | — | 88.9K | 138.9K | — | 18.5K |
| Johnson Philip LEVP & Chief Financial Officer · 7 transactions | — | 59.6K | 50.9K | 12.0K | — |
| Fust Matthew KEVP, Chief Financial Officer · 5 transactions | — | 58.9Kas of Nov 2008 | 6.3K | — | — |
| Swisher Daniel N JRPresident and COO · 15 transactions | — | 55.0Kas of Mar 2023 | 86.7K | — | — |
| Sebulsky AlanDirector · 24 transactions | — | 54.4Kas of Mar 2012 | 177.1K | 15.0K | 31.2K |
| Patil Neena MEVP & Chief Legal Officer · 53 transactions | — | 51.5K | 157.5K | — | 79.1K |
| Pearce SamanthaEVP, Chief Commercial Officer · 45 transactions | — | 50.3K | 94.5K | — | 28.2K |
| Wissel Janne LTSVP, Chief Regulatory Officer · 12 transactions | — | 48.5Kas of May 2011 | 52.0K | — | 106.7K |
| Hooper Suzanne SawochkaEVP & General Counsel · 69 transactions | — | 46.4Kas of Feb 2019 | 140.1K | — | 67.5K |
| Tobias Jeffrey KEVP, R&D & CMO · 43 transactions | — | 38.5Kas of Mar 2015 | 103.4K | — | 54.3K |
| Young Matthew P.EVP & CFO · 49 transactions | — | 36.2Kas of Mar 2019 | 59.3K | — | 20.1K |
| Gamble Carol ASVP and General Counsel · 49 transactions | — | 32.2Kas of Mar 2012 | 358.4K | — | 149.1K |
| Keegan FintanEVP, Technical Operations · 15 transactions | — | 31.8Kas of Jul 2014 | 25.0K | — | 24.3K |
| O'Keefe Kenneth WDirector · 59 transactions | — | 30.3K | 1.49M | 206.4K | 1.49M |
| Sablich KimEVP, GM of U.S. · 18 transactions | — | 28.5Kas of Jun 2023 | 45.7K | — | 9.6K |
| Smith Karen L.EVP, R&D and CMO · 16 transactions | — | 28.5Kas of Mar 2018 | 29.6K | 1.7K | — |
| Henderson Mary ElizabethSVP, Technical Operations · 12 transactions | — | 27.3K | 39.7K | — | 9.0K |
| McGill IainSVP, Europe & Rest of World · 33 transactions | — | 25.6Kas of Mar 2019 | 41.4K | — | 25.2K |
| Miller Michael PatrickEVP, US Commercial · 62 transactions | — | 22.1Kas of Mar 2020 | 35.7K | — | 12.0K |
| Larkin FinbarSVP, Technical Operations · 19 transactions | — | 21.8Kas of Mar 2023 | 21.1K | — | 9.0K |
| Enright Patrick GDirector · 262 transactions | — | 21.4Kas of Aug 2025 | 4.96M | 988.3K | 2.94M |
| Wilson Karen JSVP, Finance & PAO · 70 transactions | — | 18.7Kas of Mar 2019 | 143.2K | — | 77.2K |
| McSharry Heather AnnDirector · 32 transactions | — | 18.4K | 42.3K | — | 20.3K |
| Riedel Norbert GDirector · 34 transactions | — | 17.7K | 42.3K | — | 21.4K |
| Momtazee James CDirector · 8 transactions | — | 17.3Kas of Aug 2013 | 29.5K | — | 1.1K |
| Treacy PaulSVP, Technical Operations · 25 transactions | — | 16.5Kas of Aug 2019 | 29.8K | — | 14.2K |
| ORiordan AnneDirector · 14 transactions | — | 16.5Kas of Aug 2025 | 22.6K | — | 2.8K |
| Gray PeterDirector · 24 transactions | — | 16.1Kas of Aug 2023 | 31.7K | — | 15.6K |
| Sohn Catherine A.Director · 31 transactions | — | 14.9Kas of Aug 2023 | 38.4K | — | 23.6K |
| Tovey Christopher J.EVP, COO & Managing Director E · 6 transactions | — | 14.7Kas of Jul 2022 | 20.9K | — | 5.2K |
| DesJardin Michael A.SVP, Product Development · 2 transactions | — | 14.6Kas of Aug 2011 | 709 | — | — |
| Colligan JoanPrincipal Accounting Officer · 6 transactions | — | 14.4Kas of Nov 2010 | — | — | 93 |
| Michelson Michael WDirector · 4 transactions | — | 13.9Kas of Jan 2012 | 25.0K | — | — |
| Cook Jennifer E.Director · 13 transactions | — | 10.8Kas of Aug 2025 | 17.7K | — | 3.6K |
| Smith Mark DouglasDirector · 14 transactions | — | 9.7K | 17.7K | — | 4.7K |
| Winningham Rick EDirector · 48 transactions | — | 9.6K | 136.5K | — | 66.9K |
| Berns Paul LDirector · 30 transactions | — | 8.3Kas of Aug 2021 | 113.9K | — | 51.1K |
| Schnee ElmarDirector · 13 transactions | — | 8.3Kas of Aug 2021 | 12.7K | — | 4.4K |
| Hamill LauraDirector · 3 transactions | — | 6.9Kas of Aug 2025 | 7.2K | — | — |
| Kennedy PatrickDirector · 4 transactions | — | 6.7Kas of Aug 2025 | 8.7K | — | — |
| Carr PatriciaSVP, Chief Accounting Officer · 69 transactions | — | 6.5K | 42.4K | — | 38.1K |
| Eller Mark G.SVP, Research & Clinical Dev. · 2 transactions | — | 4.2Kas of Aug 2011 | 690 | — | — |
| Love Ted WDirector · 1 transaction | — | 1.5K | 1.5K | — | — |
| KKR Asset Management LLC +6 co-filersSee Footnotes (2) - (9) · 3 transactions | — | 0as of Aug 2011 | — | — | 70.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -16.58M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.